Schade D S, Eaton R P
Diabetes. 1977 Oct;26(10):989-96. doi: 10.2337/diab.26.10.989.
Previous studies have attributed norepinephrine's ketogenic activity to its ability to mobilize peripheral fat stores. This study was designed to determine whether norepinephrine has ketogenic activity independent of its lipolytic effect in diabetic man. Six insulin-dependent diabetic subjects were infused with pathophysiologic concentrations of norepinephrine (0.08 microgram./kg./min.). As a control for norepinephrine's lipolytic effect, a separate heparin-induced free fatty acid generation study was performed on each subject. The results demonstrate, for the first time in man, that norepinephrine has ketogenic activity independent of its lipolytic effect. Furthermore, physiologic elevations of norepinephrine concentration were also demonstrated to increase plasma glucagon concentration. Our data are consistent with the possibility that the rise in concentration of glucagon may have a participated in the catecholamine-augmented ketogenesis.
以往的研究将去甲肾上腺素的生酮活性归因于其动员外周脂肪储备的能力。本研究旨在确定去甲肾上腺素在糖尿病患者中是否具有独立于其脂解作用的生酮活性。对6名胰岛素依赖型糖尿病受试者输注病理生理浓度的去甲肾上腺素(0.08微克/千克/分钟)。作为去甲肾上腺素脂解作用的对照,对每位受试者进行了一项单独的肝素诱导游离脂肪酸生成研究。结果首次在人体中证明,去甲肾上腺素具有独立于其脂解作用的生酮活性。此外,还证明去甲肾上腺素浓度的生理性升高会增加血浆胰高血糖素浓度。我们的数据与胰高血糖素浓度升高可能参与儿茶酚胺增强的生酮作用这一可能性相一致。